Phase 3 Recruiting NIH
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrin…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05256225
Sites in Illinois: - Northwest Community Hospital — Arlington Heights, Illinois
- Rush-Copley Medical Center — Aurora, Illinois
- Centralia Oncology Clinic — Centralia, Illinois
- Northwestern University — Chicago, Illinois
- John H Stroger Jr Hospital of Cook County — Chicago, Illinois
Phase 3 Recruiting NIH
This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07198074
Sites in Illinois: - Cancer Care Specialists of Illinois - Decatur — Decatur, Illinois
- Decatur Memorial Hospital — Decatur, Illinois
- OSF Saint Francis Medical Center — Peoria, Illinois
- Southern Illinois University School of Medicine — Springfield, Illinois
- Springfield Clinic — Springfield, Illinois
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response …
Sponsor: Karyopharm Therapeutics Inc
NCT ID: NCT05611931
Sites in Illinois: - Illinois Cancer Specialists — Arlington Heights, Illinois
- NorthShore University Health System — Evanston, Illinois
Phase 3 Recruiting Industry
This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 s…
Sponsor: AstraZeneca
NCT ID: NCT07044336
Sites in Illinois: - Research Site — Chicago, Illinois
- Research Site — Peoria, Illinois
- Research Site — Urbana, Illinois
Phase 3 Recruiting Industry
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progress…
Sponsor: AstraZeneca
NCT ID: NCT06989112
Sites in Illinois: - Research Site — Arlington Heights, Illinois
- Research Site — Evanston, Illinois
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Stand…
Sponsor: NRG Oncology
NCT ID: NCT05646316
Sites in Illinois: - Northwestern University — Chicago, Illinois
- Northwestern Medicine Cancer Center Warrenville — Warrenville, Illinois
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicate…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06952504
Sites in Illinois: - University of Chicago Medical Center ( Site 5002) — Chicago, Illinois
Phase 2, Phase 3 Recruiting Industry
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part…
Sponsor: Kartos Therapeutics, Inc.
NCT ID: NCT05797831
Sites in Illinois: - Dr. Sudarshan K. Sharma, Ltd. — Hinsdale, Illinois
Phase 3 Recruiting Academic/Other
This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer. Short course va…
Sponsor: University of Utah
NCT ID: NCT03422198
Sites in Illinois: - Loyola University Medical Center — Maywood, Illinois
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Illinois: - Advocate Good Shepherd Hospital — Barrington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- SIH Cancer Institute — Carterville, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
Phase 2 Recruiting NIH
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite tre…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554328
Sites in Illinois: - Advocate Good Shepherd Hospital — Barrington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
- Centralia Oncology Clinic — Centralia, Illinois
Phase 2 Recruiting NIH
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05112601
Sites in Illinois: - University of Illinois — Chicago, Illinois
- Carle at The Riverfront — Danville, Illinois
- Carle Physician Group-Effingham — Effingham, Illinois
- Carle Physician Group-Mattoon/Charleston — Mattoon, Illinois
- Carle BroMenn Medical Center — Normal, Illinois
Phase 2 Recruiting Industry
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Sponsor: Acrivon Therapeutics
NCT ID: NCT05548296
Sites in Illinois: - Northwestern Medicine — Chicago, Illinois
- University of Illinois Cancer Center — Chicago, Illinois
- University of Chicago Medicine — Chicago, Illinois
- Carle Cancer Center — Urbana, Illinois
Phase 2 Recruiting Network
This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/R…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05640999
Sites in Illinois: - Northwestern University — Chicago, Illinois
- Northwestern Medicine Orland Park — Orland Park, Illinois
- Northwestern Medicine Cancer Center Warrenville — Warrenville, Illinois
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Illinois: - Hope and Healing Cancer Services — Hinsdale, Illinois
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …
Sponsor: Eisai Inc.
NCT ID: NCT04300556
Sites in Illinois: - Northwestern Memorial Hospital — Chicago, Illinois
- Ascension Illinois-Skokie Infustion Center — Skokie, Illinois
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Illinois: - Lurie Children's Hospital-Chicago — Chicago, Illinois
Phase 1, Phase 2 Recruiting Academic/Other
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer.…
Sponsor: Alliance Foundation Trials, LLC.
NCT ID: NCT04486352
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Illinois: - Orchard Healthcare Research Inc. — Skokie, Illinois
Phase 1, Phase 2 Recruiting Industry
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Illinois: - University of Chicago Medical Center — Chicago, Illinois
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Illinois: - Affiliated Oncologists — Chicago Ridge, Illinois
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Illinois: - University of Chicago Medical Center — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Sponsor: Volastra Therapeutics, Inc.
NCT ID: NCT05902988
Sites in Illinois: - Kellogg Cancer Center — Evanston, Illinois
Phase 1, Phase 2 Recruiting Industry
This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT04590326
Sites in Illinois: - Robert H. Lurie Comprehensive Cancer Center of Northwestern University — Chicago, Illinois
- University of Chicago Medical Center — Chicago, Illinois